Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Dec;4(4):209-219.
doi: 10.1093/nop/npw016. Epub 2016 Aug 26.

Pivotal therapeutic trials for infiltrating gliomas and how they affect clinical practice

Rimas V Lukas  1 , Maciej M Mrugala  1
Affiliations
Review

Pivotal therapeutic trials for infiltrating gliomas and how they affect clinical practice

Rimas V Lukas et al. Neurooncol Pract. 2017 Dec.

Abstract

The therapeutic landscape of the management of low- and high-grade infiltrating gliomas continues to evolve. Daily clinical decision making in neuro-oncology clinics across the US is frequently challenging, especially for anaplastic and low grade primary brain tumors. The focus of this review is centered on treatments which are approved by the FDA and/or featured in the NCCN Guidelines. Systemic therapy trials using a variety of agents such as temozolomide, bevacizumab, and procarbazine, lomustine, vincristine (PCV), and lastly trials of local therapies including surgical trials using carmustine impregnated wafers as well as trials investigating the administration of tumor treating fields are evaluated. Pivotal trials on the treatment of the primary brain tumors are discussed in detail along with associated correlative studies.

Keywords: bevacizumab; glioma; lomustine; temozolomide; tumor treating fields.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Axial T1 post-contrast MRI of a patient with glioblastoma demonstrating substantial enhancement and surrounding edema with associated midline shift (A). Marked decrease in the enhancing lesion and resolution of the midline shift is noted after the initiation of bevacizumab. (B) These findings were associated with notable clinical improvement.
See this image and copyright information in PMC

References

    1. Newlands ES, Blackledge GR, Slack JA, et al. Phase I trial of temozolomide (CCRG 81045, M&B 39831, NSC 362856). Br J Cancer. 1992;65(2):287–291. - PMC - PubMed
    1. Bower M, Newlands ES, Bleehen NM, et al. Multicenter CRC phase II trial in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol. 1997;40(6):484–488. - PubMed
    1. Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme in first relapse. Br J Cancer. 2000;83(5):588–593. - PMC - PubMed
    1. Osoba D, Brada M, Yung WK, Prados MD. Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. Eur J Cancer. 2000;36(14):1788–1795. - PubMed
    1. Stupp R, Dietrich PY, Ostermann Kraljevic S, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol. 2002;20(5):1375–1382. - PubMed